Structural knowledge of the active pharmaceutical ingredient (API) solid form is extremely important in drug development. Conventional API solid forms include polymorphs of the pure drug molecule, its salts, solvates/hydrates and co-crystals between the drug molecule and other pharmaceutically accepted co-formers. Due to differences in lattice interactions, the solid forms adopted by an API can exhibit large differences in their stability, solubility and dissolution properties, and ultimately, the overall bioavailability of the API. Therefore, the physicochemical properties of solid formulated drugs can be tailored by specific solid form selection and identifying and characterising the available solid forms of an API is critical for selecting, or even engineering, the optimal solid form. Preparing and characterising a large proportion of the available solid forms of an API can be a challenging process that often requires a sound screening strategy with intelligent and high-throughput experimentation .